Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus

AZ and Sanofi’s Antibody Success Against The Often Deadly Infection

 
• By Andrew McConaghie
Boy_Inhaler
Respiratory synctial virus (RSV) is one of the biggest causes of hospitalization and death in infants worldwide.

More from Business

More from Scrip